MARKET

VTVT

VTVT

VTV THERAPEUTICS
NASDAQ

Real-time Quotes | Nasdaq Last Sale

1.150
+0.010
+0.88%
Opening 15:44 12/06 EST
OPEN
1.130
PREV CLOSE
1.140
HIGH
1.180
LOW
1.110
VOLUME
245.01K
TURNOVER
--
52 WEEK HIGH
4.750
52 WEEK LOW
1.110
MARKET CAP
103.54M
P/E (TTM)
-14.1451
1D
5D
1M
3M
1Y
5Y
Here's Why vTv Therapeutics (VTVT) is Poised for a Turnaround After Losing 15.2% in 4 Weeks
vTv Therapeutics (VTVT) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential...
Zacks · 3d ago
BRIEF-vTv Therapeutics Inc Says Rudy Howard Announced His Resignation As Chief Financial Officer
reuters.com · 3d ago
Ultragenyx (RARE) Begins Dosing in Phase I/II Study of UX053
Zacks.com · 4d ago
Deciphera (DCPH) to Prioritize Key Pipeline Drugs, Cut Jobs
Zacks.com · 5d ago
Blueprint Medicines (BPMC) Set to Acquire Lengo Therapeutics
Zacks.com · 6d ago
BioCryst (BCRX) Begins Enrollment in PNH Study on BCX9930
Zacks.com · 6d ago
Selecta (SELB) Down on FDA's Clinical Hold on Phase I/II Study
Zacks.com · 11/25 15:56
Triad pharmaceutical company ranks high in Deloitte’s 2021 Technology Fast 500 list
vTv Therapeautics was one of seven North Carolina companies — and the only in the Triad — to make Deloitte's 2021 Technology Fast 500 list.
American City Business Journals · 11/22 11:06
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of VTVT. Analyze the recent business situations of VTV THERAPEUTICS through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 2 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

0.00%Strong Buy
100.00%Buy
0.00%Hold
0.00%Under-perform
0.00%Sell
Analyst Price Target
The average VTVT stock price target is 6.75 with a high estimate of 7.50 and a low estimate of 6.00.
High7.50
Average6.75
Low6.00
Current 1.150
EPS
Actual
Estimate
-0.06-0.04-0.020.00
Q4 2020
Q1 2021
Q2 2021
Q3 2021
Q4 2021
Institutional Holdings
Institutions: 47
Institutional Holdings: 3.62M
% Owned: 4.02%
Shares Outstanding: 90.04M
TypeInstitutionsShares
Increased
7
200.76K
New
6
302.72K
Decreased
11
452.43K
Sold Out
17
1.01M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-2.80%
Pharmaceuticals & Medical Research
-0.63%
Key Executives
Chairman/Executive Director
Robin Abrams
President/Chief Executive Officer/Director
Deepa Prasad
Director
Hersh Kozlov
Director
Richard Nelson
Independent Director
John Fry
Independent Director
Noel Spiegel
Independent Director
Howard Weiner
No Data
  • All
  • Financials
  • Insiders
More
About VTVT
vTv Therapeutics Inc. is a clinical-stage pharmaceutical company that is engaged in the discovery and development of orally administered small molecule drug candidates. It is developing a program for the treatment of type I diabetes TTP399 and for psoriasis HPP737. TTP399 is an orally administered, small molecule, liver-selective glucokinase activator (GKA) in development potential oral anti-diabetic for the treatment of type I diabetes. TTP399 completed the SimpliciT-I Study, a Phase II trial in patients with type I diabetes as an add-on to insulin therapy. The Company is also conducting a multiple ascending dose Phase I study of HPP737, an orally administered phosphodiesterase type IV inhibitor, to assess the pharmacokinetics, pharmacodynamics, safety and tolerability of HPP737 in healthy volunteers as part of its psoriasis program. Its TTP273 is an oral, small molecule, glucagon-like peptide I (GLP-1) receptor agonist being evaluated for the treatment of type II diabetes mellitus.

Webull offers kinds of vTv Therapeutics Inc stock information, including NASDAQ:VTVT real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, VTVT stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading VTVT stock methods without spending real money on the virtual paper trading platform.